Evaluation of the effects of favipiravir (T-705) on the lung tissue of healty rats: An experimental study.

Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor widely used during the COVID-19 pandemic, effectively reduces viral load but has been linked to inflammatory changes in tissues such as the liver and kidneys. High-dose and prolonged use of favipiravir for COVID-19 raises concerns about its potential toxic effects on the lungs, particularly in patients with pre-existing pulmonary conditions. This study investigated favipiravir's effects on lung tissue in healthy rats. Experimental groups included a Control (saline) and three favipiravir doses: Low (200 mg/kg/day loading, 100 mg/kg/day maintenance), Medium (400 mg/kg/day loading, 200 mg/kg/day maintenance), and High (600 mg/kg/day loading, 300 mg/kg/day maintenance), all administered via gavage for 10 days. Histopathological analysis showed normal lung structure in the Control group, while favipiravir-treated groups exhibited Bronchus-Associated Lymphoid Tissue (BALT) enlargement, inflammation, fibrosis, and hemorrhage. Immunohistochemical analysis revealed dose-dependent increases in TNF-α, TGF-β, IL-6, IFN-γ, IL1-β, α-SMA, and collagen-1, especially in the High-dose group (p < 0.05). These findings suggest favipiravir may induce lung inflammation and fibrosis, emphasizing the need for careful evaluation of its safety in clinical settings, particularly for COVID-19 treatment. Future research should investigate the underlying mechanisms of these effects with clinical studies to assess their relevance to humans, high-risk pulmonary patients.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2025 Elsevier Ltd. All rights reserved.)